

Identification of next-generation EGFR degraders to treat Non-Small Cell Lung Cancer (NSCLC) patients

Cyrus Therapeutics



ONCOLOGY	Lead
Product Type	Small Molecule Heterobifunctional Degradar (PROTAC)
Indication	Non-small cell lung cancer
Target	Multiple EGFR mutants including C797S mutation
MoA(Mechanism of Action)	Formation of ternary complex (Mutant EGFR::PROTAC::E3 ligase) → Mutant EGFR ubiquitination by bifunctional EGFR degraders → Ubiquitinated mutant EGFR proteins degradation by proteasome → Mutant EGFR dependent NSCLC cell death
Competitiveness	First-In Class
Development Stage	Lead
Route of Administration	Intravenous